These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21359555)

  • 21. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
    Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
    Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE study.
    Saraux A; Combe B; Blin P; Bregman B; Chartier M; Durieux-Mehlman S; Guillemin F
    Clin Exp Rheumatol; 2010; 28(3):325-32. PubMed ID: 20460034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis.
    Brady BL; Tkacz JP; Lofland J; Meyer R; Bolge SC
    Clin Ther; 2015 Sep; 37(9):2028-36. PubMed ID: 26210073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are rheumatologists' treatment decisions influenced by patients' age?
    Fraenkel L; Rabidou N; Dhar R
    Rheumatology (Oxford); 2006 Dec; 45(12):1555-7. PubMed ID: 16690762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Regression of peripheral and pulmonary rheumatoid nodules under therapy with rituximab].
    Braun MG; Wagener P
    Z Rheumatol; 2013 Mar; 72(2):166-71. PubMed ID: 23052405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eficiency of different doses of rituximab in rheumatoid arthritis.
    Mena-Vázquez N; Manrique-Arija S; Ureña-Garnica I; Romero-Barco CM; Jiménez-Núñez FG; Coret V; Irigoyen-Oyarzábal MV; Fernández-Nebro A
    Reumatol Clin; 2016; 12(3):139-45. PubMed ID: 26458761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis.
    Mishra R; Singh V; Pritchard CH
    Rheumatol Int; 2011 Apr; 31(4):481-4. PubMed ID: 20091035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time to consultation and disease-modifying antirheumatic drug treatment of patients with rheumatoid arthritis--northern Alberta perspective.
    Nanji JA; Choi M; Ferrari R; Lyddell C; Russell AS
    J Rheumatol; 2012 Apr; 39(4):707-11. PubMed ID: 22337235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis.
    Roll P; Mahmood Z; Muhammad K; Feuchtenberger M; Dörner T; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):347-53. PubMed ID: 25897997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
    Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
    Finckh A; Ciurea A; Brulhart L; Möller B; Walker UA; Courvoisier D; Kyburz D; Dudler J; Gabay C;
    Ann Rheum Dis; 2010 Feb; 69(2):387-93. PubMed ID: 19416802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
    Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
    Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions.
    Emadi SA; Hammoudeh M; Mounir M; Mueller RB; Wells AF; Sarakbi HA
    J Int Med Res; 2017 Apr; 45(2):733-743. PubMed ID: 28415924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
    Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
    J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.
    Xia Z; Lyu J; Hou N; Song L; Li X; Liu H
    Z Rheumatol; 2016 Oct; 75(8):828-833. PubMed ID: 26508503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
    Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
    Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.